Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Published in and
1 other channel

Journal Scan / Research · {not yet published}

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine vs Temozolomide in Combination With Radiotherapy in Patients With IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

L. Gonzalez Castro MD, PhD

Journal of Clinical Oncology
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
J. Clin. Oncol 2024 Oct 02;[EPub Ahead of Print], SEO Kacimi, C Dehais, L Feuvret, O Chinot, C Carpentier, C Bronnimann, E Vauleon, A Djelad, E Cohen-Jonathan Moyal, O Langlois, M Campone, M Ducloie, G Noel, S Cuzzubbo, L Taillandier, C Ramirez, N Younan, P Menei, F Dhermain, C Desenclos, F Ghiringhelli, V Bourg, D Ricard, T Faillot, R Appay, E Tabouret, L Nichelli, B Mathon, A Thomas, S Tran, F Bielle, A Alentorn, JB Iorgulescu, PY Boëlle, K Labreche, K Hoang-Xuan, M Sanson, A Idbaih, D Figarella-Branger, F Ducray, M Touat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.